These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21945513)

  • 1. Re: Prospective evaluation of operating characteristics of prostate cancer detection biomarkers: Y. Liang, D. P. Ankerst, N. S. Ketchum, B. Ercole, G. Shah, J. D. Shaughnessy, Jr., R. J. Leach and I. M. Thompson J Urol 2011; 185: 104-110.
    Catalona WJ
    J Urol; 2011 Nov; 186(5):2131-2; author reply 2132. PubMed ID: 21945513
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Yearly prostate specific antigen and digital rectal examination fluctuations in a screened population: D. P. Ankerst, R. Miyamoto, P. V. Nair, B. H. Pollock, I. M. Thompson and D. J. Parekh J Urol 2009; 181: 2071-2076.
    Hammond I; Bunting PS
    J Urol; 2010 Jan; 183(1):396. PubMed ID: 19926100
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer: I. M. Thompson, D. P. Ankerst, R. Etzioni and T. Wang J Urol 2008; 180: 1219-1222.
    Walsh PC
    J Urol; 2009 Mar; 181(3):1499; author reply 1499-500. PubMed ID: 19157429
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy I. M. Thompson, C. M. Tangen, D. P. Ankerst, C. Chi, M. S. Lucia, P. Goodman, H. Parnes and C. A. Coltman, Jr. J Urol 2008; 180: 544-547.
    Atmaca AF; Balbay MD
    J Urol; 2009 May; 181(5):2387-8. PubMed ID: 19303084
    [No Abstract]   [Full Text] [Related]  

  • 5. Re: Timing of Adverse Prostate Cancer Reclassification on First Surveillance Biopsy: Results from the Canary Prostate Cancer Active Surveillance Study: L. C. Macleod, W. J. Ellis, L. F. Newcomb, Y. Zheng, J. D. Brooks, P. R. Carroll, M. E. Gleave, R. S. Lance, P. S. Nelson, I. M. Thompson, Jr., A. A. Wagner, J. T. Wei and D. W. Lin J Urol 2017;197:1026-1033.
    Denize J; Nouhaud FX; Cornu JN; Pfister C
    J Urol; 2017 Sep; 198(3):709-711. PubMed ID: 28579000
    [No Abstract]   [Full Text] [Related]  

  • 6. Re: The Prostate Cancer Prevention Trial: design, biases and interpretation of study results. P. J. Goodman, I. M. Thompson, Jr., C. M. Tangen, J. J. Crowley, L. G. Ford and C. A. Coltman, Jr., J Urol, 175: 2234-2242, 2006.
    Walsh PC
    J Urol; 2006 Dec; 176(6 Pt 1):2744; author reply 2744. PubMed ID: 17085206
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. S. J. Freedland, E. A. Platz, J. C. Presti Jr., W. J. Aronson, C. L. Amling, C. J. Kane and M. K. Terris. J Urol, 175: 500-504, 2006.
    Stamatiou K; Alevizos A; Mariolis A; Sofras F
    J Urol; 2006 Sep; 176(3):1251-2; author reply 1252. PubMed ID: 16890735
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer: S. Loeb, M. G. Sanda, D. L. Broyles, S. S. Shin, C. H. Bangma, J. T. Wei, A. W. Partin, G. G. Klee, K. M. Slawin, L. S. Marks, R. H. N. van Schaik, D. W. Chan, L. J. Sokoll, A. B. Cruz, I. A. Mizrahi and W. J. Catalona J Urol 2015;193:1163-1169.
    Shah N; Ioffe V
    J Urol; 2015 Dec; 194(6):1825-6. PubMed ID: 26354886
    [No Abstract]   [Full Text] [Related]  

  • 9. Re: Smaller prostate size predicts high grade prostate cancer at final pathology. M. R. Newton, S. Phillips, S. S. Chang, P. E. Clark, M. S. Cookson, R. Davis, J. H. Fowke, S. D. Herrell, R. Baumgartner, R. Chan, V. Mishra, J. D. Blume, J. A. Smith, Jr. and D. A. Barocas. J Urol 2010; 184: 930-937.
    Calışkan S
    J Urol; 2011 Apr; 185(4):1537-8; author reply 1538. PubMed ID: 21349547
    [No Abstract]   [Full Text] [Related]  

  • 10. Re: Small prostate size and high grade disease--biology or artifact?: J. J. Liu, J. D. Brooks, M. Ferrari, R. Nolley and J. C. Presti, Jr. J Urol 2011; 185: 2108-2111.
    Calışkan S
    J Urol; 2011 Dec; 186(6):2504; author reply 2504-5. PubMed ID: 22019038
    [No Abstract]   [Full Text] [Related]  

  • 11. Re: prostate specific antigen decrease and prostate cancer diagnosis: antibiotic versus placebo prospective randomized clinical trial: R. M. Stopiglia, U. Ferreira, M. M. Silva, W. E. Matheus, f. Denardi and L. O. Reis J Urol 2010; 183: 940-945.
    Yoon DK; Park HS; Park JY
    J Urol; 2010 Nov; 184(5):2214-5; author reply 2215. PubMed ID: 20864135
    [No Abstract]   [Full Text] [Related]  

  • 12. Re: Early detection of prostate cancer: AUA guideline: H. B. Carter, P. C. Albertsen, M. J. Barry, R. Etzioni, S. J. Freedland, K. L. Greene, L. Holmberg, P. Kantoff, B. R. Konety, M. H. Murad, D. F. Penson and A. L. Zietman J Urol 2013; 190: 419-426.
    Moul JW; Walsh PC; Rendell MS; Lynch HT; Leslie SW; Kosoko-Lasaki O; Fitzgibbons WP; Powell I; D'Amico AV; Catalona WJ
    J Urol; 2013 Sep; 190(3):1134-7. PubMed ID: 23871525
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. S. E. Eggener, K. A. Roehl, O. Yossepowitch and W. J. Catalona, J Urol 2006; 176: 1399-1403.
    Wagner MD; Daneshmand S; Sokoloff M; Barry JM
    J Urol; 2007 Jun; 177(6):2396; author reply 2396-7. PubMed ID: 17509368
    [No Abstract]   [Full Text] [Related]  

  • 14. Re: Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer. S. T. dos Reis, J. Pontes, Jr., F. E. Villanova, P. M. D. Borra, A. A. Antunes, M. F. Dall'oglio, M. Srougi and K. R. M. Leite. J Urol 2009; 181: 2320-2325.
    Ahirwar DK; Mittal RD
    J Urol; 2010 Mar; 183(3):1258. PubMed ID: 20097381
    [No Abstract]   [Full Text] [Related]  

  • 15. Re: Chemoprevention of prostate cancer. I. M. Thompson, C. M. Tangen, P. J. Goodman, M. S. Lucia and E. A. Klein. J Urol 2009; 182: 499-508.
    Schellhammer PF
    J Urol; 2010 Mar; 183(3):1258-9; author reply 1259. PubMed ID: 20097380
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial I. M. Thompson, C. M. Tangen, J. Paradelo, M. S. Lucia, G. Miller, D. Troyer, E. Messing, J. Forman, J. Chin, G. Swanson, E. Canby-Hagino and E. D. Crawford J Urol 2009; 181: 956-962.
    Cheng T; Heng DY; Stewart D
    J Urol; 2009 Nov; 182(5):2531-2; discussion 2532-4. PubMed ID: 19766252
    [No Abstract]   [Full Text] [Related]  

  • 17. Re: Variation in Surgical Margin Status by Surgical Approach among Patients Undergoing Partial Nephrectomy for Small Renal Masses: W. Tabayoyong, R. Abouassaly, J. E. Kiechle, E. E. Cherullo, N. J. Meropol, N. D. Shah, S. Dong, R. H. Thompson, M. C. Smaldone, H. Zhu, S. Ialacci and S. P. Kim J Urol 2015;194:1548-1553.
    Bhattar R; Yadav SS; Priyadarshi S; Tomar V
    J Urol; 2016 Sep; 196(3):960. PubMed ID: 27311408
    [No Abstract]   [Full Text] [Related]  

  • 18. Re: Monique J. Roobol, Ewout W. Steyerberg, Ries Kranse, et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010;57:79-85.
    Morrod D
    Eur Urol; 2010 Sep; 58(3):327; author reply 328-30. PubMed ID: 20598799
    [No Abstract]   [Full Text] [Related]  

  • 19. Re: a prospective study to evaluate the role of complexed prostate specific antigen and free/total prostate specific antigen ratio for the diagnosis of prostate cancer. I.D.C. Mitchell, B.L. Croal, A. Dickie, N.P. Cohen and I. Ross. J Urol, 165: 1549-1553, 2001.
    Stephan C; Jung K; Schnorr D; Lein M; Sinha P; Loening SA
    J Urol; 2002 Jan; 167(1):259-60. PubMed ID: 11743329
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: re: early detection of prostate cancer: AUA guideline: J. W. Moul, P. C. Walsh, M. S. Rendell, H. T. Lynch, S. W. Leslie, O. Kosoko-Lasaki, W. P. Fitzgibbons, I. Powell, A. V. D'Amico and W. J. Catalona J Urol 2013; 190: 1134-1139.
    Shah N; Ioffe V
    J Urol; 2014 Mar; 191(3):871. PubMed ID: 24355135
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.